Live Breaking News & Updates on Novel Targeted|Page 2

Home / Top News / Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial 
reduction in baseline corticosteroid use
Dose-dependent reduction of CD6 expression on CD4+ and CD8+ T cells is consistent with itolizumab mechanism of action
LA JOLLA, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, presented interim data from the EQUATE clinical trial supporting itolizumab’s potential as a first-line tre ....

Stephen Connelly , John Koreth , Michael Moore , Katherine Carlyle Smith , Canale Communications , Harvard Medical School , Equillium Inc , Dana Farber Cancer Institute , Translational Research , Investor Relations Corporate Communications , Novel Targeted , Interim Results , Equate Study , Associate Professor , Stem Cell Transplantation , Oral Presentation , Graft Versus Host Disease , Private Securities Litigation Reform Act , Investor Relations , ஸ்டீபன் கோநிலீ , மைக்கேல் மூர் , க்யாதரிந் கார்லைல் ஸ்மித் , கால்வாய் தகவல்தொடர்புகள் , ஹார்வர்ட் மருத்துவ பள்ளி , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , மொழிபெயர்ப்பு ஆராய்ச்சி ,